A comparison of the beta1-selectivity of three beta1-selective beta-blockers - PubMed (original) (raw)
Clinical Trial
A comparison of the beta1-selectivity of three beta1-selective beta-blockers
S L Nuttall et al. J Clin Pharm Ther. 2003 Jun.
Abstract
Objective: To determine the relative beta1-selectivity of three beta-blockers (nebivolol, bisoprolol and atenolol), administered orally at normal therapeutic doses, by assessing their impact on the beta2-mediated, haemodynamic and biochemical responses to a terbutaline infusion, which decreases serum potassium and increases serum glucose and insulin.
Methods: Twenty-four healthy volunteers (14 men, 10 women), with no history of respiratory disease, attended on five separate occasions; beta-blockers (nebivolol 5 mg, bisoprolol 10 mg, atenolol 50 and 100 mg) or placebo were supplied in random order. Three baseline blood samples were collected at 65-85 min post-beta-blocker. A 60-min terbutaline infusion was started 90 min after taking the beta-blocker. Blood samples were taken and blood pressure and heart rate recorded at 15 min intervals up to 30-min post-infusion. Blood samples were analysed for serum potassium, glucose and insulin concentrations.
Results: Terbutaline increased heart rate. Pretreatment with nebivolol caused a modest and non-significant reduction in terbutaline-induced tachycardia whilst bisoprolol produced a more marked effect. Atenolol at both 50 and 100 mg doses caused a highly significant reduction in terbutaline-induced tachycardia. All active preparations had a comparable impact on the terbutaline-induced increase in systolic blood pressure, but the drugs had no impact on the changes produced in diastolic blood pressure. After pretreatment with placebo, the terbutaline infusion caused a significant decrease in serum potassium and increases in serum glucose and insulin. Pretreatment with nebivolol had no discernible effect on potassium compared with placebo. In contrast, when compared with either placebo or nebivolol, bisoprolol (P < 0.01) and both doses of atenolol (P < 0.001) significantly attenuated the hypokalaemic effect of terbutaline. Treatment with nebivolol and bisoprolol modestly but significantly reduced the terbutaline-induced increases in glucose (P < 0.05). The blocking effects of both doses of atenolol were highly significant (P < 0.001) when compared with placebo and also significant (P < 0.05 and P < 0.01, respectively) when compared with nebivolol and bisoprolol. A similar pattern of responses with the different beta-blocker treatments was observed for the effects on insulin concentrations during the terbutaline infusion.
Conclusion: The beta1-selectivity of three different beta1-blockers has been demonstrated in healthy volunteers using the blocking of biochemical and haemodynamic responses to a beta2 stimulus. Terbutaline alone caused an increase in heart rate, a rise in systolic blood pressure, a fall in serum potassium and a rise in both serum glucose and insulin. In this study, for both haemodynamic and biochemical responses, atenolol 100 mg had the greatest beta2-blocking effect, nebivolol 5 mg the least. Bisoprolol 10 mg and atenolol 50 mg had intermediate effects; bisoprolol was the more beta1-selective of these two.
Similar articles
- Effects of nebivolol, atenolol and propranolol on in vivo cardiovascular and metabolic responses to isoproterenol in dogs.
Bowden CR, Marchione CS. Bowden CR, et al. J Pharmacol Exp Ther. 1989 Nov;251(2):599-605. J Pharmacol Exp Ther. 1989. PMID: 2572694 - Exercise tolerance with nebivolol and atenolol.
Van Bortel LM, van Baak MA. Van Bortel LM, et al. Cardiovasc Drugs Ther. 1992 Jun;6(3):239-47. doi: 10.1007/BF00051145. Cardiovasc Drugs Ther. 1992. PMID: 1353367 Clinical Trial. - Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure.
Van Nueten L, De Crée J. Van Nueten L, et al. Cardiovasc Drugs Ther. 1998 Sep;12(4):339-44. doi: 10.1023/a:1007760515117. Cardiovasc Drugs Ther. 1998. PMID: 9825177 Clinical Trial. - Nebivolol: endothelium-mediated vasodilating effect.
Ritter JM. Ritter JM. J Cardiovasc Pharmacol. 2001 Dec;38 Suppl 3:S13-6. doi: 10.1097/00005344-200112003-00003. J Cardiovasc Pharmacol. 2001. PMID: 11811387 Review. - Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.
Weiss R. Weiss R. Vasc Health Risk Manag. 2006;2(3):303-8. doi: 10.2147/vhrm.2006.2.3.303. Vasc Health Risk Manag. 2006. PMID: 17326335 Free PMC article. Review.
Cited by
- Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
AlHabeeb W, Mrabeti S, Abdelsalam AAI. AlHabeeb W, et al. Cardiovasc Drugs Ther. 2022 Oct;36(5):959-971. doi: 10.1007/s10557-021-07205-y. Epub 2021 Jun 9. Cardiovasc Drugs Ther. 2022. PMID: 34106365 Free PMC article. Review. - The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials.
Brugts JJ, Bertrand M, Remme W, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML, Boersma E. Brugts JJ, et al. Cardiovasc Drugs Ther. 2017 Aug;31(4):391-400. doi: 10.1007/s10557-017-6747-9. Cardiovasc Drugs Ther. 2017. PMID: 28856537 Free PMC article. - The crosstalk between bone remodeling and energy metabolism: A translational perspective.
Karsenty G, Khosla S. Karsenty G, et al. Cell Metab. 2022 Jun 7;34(6):805-817. doi: 10.1016/j.cmet.2022.04.010. Epub 2022 May 10. Cell Metab. 2022. PMID: 35545088 Free PMC article. Review. - Beta-blocker use in heart failure patients with airways disease.
Shaw SM, Hasleton J, Williams SG. Shaw SM, et al. Clin Cardiol. 2009 Jul;32(7):393-6. doi: 10.1002/clc.20590. Clin Cardiol. 2009. PMID: 19609894 Free PMC article. - Effects of Beta-Blocker Titration on Glucose Homeostasis in Heart Failure.
Vardeny O, Zebrack J, Gilbert EM, Cheang KI. Vardeny O, et al. J Pharm Technol. 2009;25(2):71-78. doi: 10.1177/875512250902500202. J Pharm Technol. 2009. PMID: 19675680 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources